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 Abstract 
 
Mitochondrial disorders are clinically and genetically heterogeneous, and are associated with a 
variety of disease mechanisms. Defects of mitochondrial protein synthesis account for the largest 
subgroup of disorders manifesting with impaired respiratory chain capacity; yet, only a few have 
been linked to dysfunction in the protein components of the mitochondrial ribosomes. Here, we 
report a subject presenting with dyskinetic cerebral palsy and partial agenesis of the corpus 
callosum, while histochemical and biochemical analyses of skeletal muscle revealed signs of 
mitochondrial myopathy. Using exome sequencing, we identified a homozygous variant, 
c.215C>T, in MRPS25, which encodes for a structural component of the 28S small subunit of the 
mitochondrial ribosome (mS25). The variant segregates with the disease, and substitutes a highly 
conserved proline residue with leucine (p.P72L) that, based on the high resolution structure of the 
28S ribosome, is predicted to compromise inter-protein contacts and destabilize the small subunit. 
Concordant with the in silico analysis, patient’s fibroblasts showed decreased levels of MRPS25 
and other components of the 28S subunit. Moreover, mutant fibroblasts showed a dearth of the 
28S assembly accompanied by impaired mitochondrial translation and decreased levels of 
multiple respiratory chain subunits. Crucially, these abnormalities were rescued by transgenic 
expression of wild-type MRPS25 in the mutant fibroblasts. Collectively, our data demonstrate the 
pathogenicity of the p.P72L variant, and identified MRPS25 as a new cause of mitochondrial 
translation defect.  
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 Introduction 
 
Mitochondrial disorders encompass a broad range of pathologies, manifesting as tissue-specific or 
multisystemic diseases, with onset at any stage of life. Genetically, they can arise from lesions 
either in the mitochondrial genome (mtDNA) or in nuclear genes required for the maintenance 
and function of the mitochondria. The advent of next generation sequencing has greatly 
accelerated the identification of causative disease genes (1). Several of these are involved in the 
translation of the 13 proteins encoded by the mtDNA that, although few in number, are essential 
for oxidative phosphorylation (OXPHOS), and thus for energy production. Central to the process 
of mitochondrial protein synthesis is the mitochondrial ribosome (mitoribosome). In mammals, it 
comprises a large (mt-LSU, 39S) and a small (mtSSU, 28S) subunit, together sedimenting as 55S 
particles. The RNA components of the mitoribosome are encoded by mtDNA, whereas the 
constituent polypeptides (MRPs), some 80 in number, derive from nuclear genes (2).  Despite its 
complexity, defects in the mitoribosome account for only a small minority of mitochondrial 
translation disorders. To date, mutations in MRPs have been reported for: MRPS2, MRPS7, 
MRPS16, MRPS14, MRPS22, MRPS23 MRPS34, MRPL3, MRPL12, and MRPL44 (3-14). The 
clinical and biochemical phenotypes vary, but often includes neonatal or childhood onset with 
brain abnormalities, cardiac involvement, increased lactate levels and multiple respiratory chain 
deficiencies. Here, we report a homozygous MRPS25 mutation in a patient presenting with 
mitochondrial encephalomyopathy. Detailed functional analyses supported the pathogenicity of 
the detected variant and demonstrate the important role for MRPS25 in mitochondrial ribosome 
function. 
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 Results 
 
Case report 
The proband is a 25-year-old male, first child of healthy non-consanguineous parents (Fig. 1A). 
He was born at term with a birth weight of 2.5 kg following a normal pregnancy, although at 28 
weeks intra-uterine growth restriction was detected. After an uneventful perinatal period, 
psychomotor delay became evident at 8 months when his weight was 6.34 kg (beneath the 3rd 
centile) and head circumference was 40 cm (beneath the 3rd centile). At 10 months he exhibited 
poor head control, choreoathetoid distal limb movements associated with increased extensor tone, 
and brisk reflexes. A brain MRI scan at this time revealed partial agenesis of corpus callosum and 
under-development of the frontal and parietal temporal regions, while extensive investigation for 
an underlying metabolic disorder, including measurement of mucopolysaccharides and 
oligosaccharides, serum copper level, white cell enzymes, very long chain fatty acids, carnitine 
levels, pyruvate dehydrogenase activity, and urine organic acid, failed to detect any abnormalities. 
Karyotyping and echocardiogram were normal too, while blood and CSF lactate showed 
borderline values (2.8mmol/L; 2.7mmol/l, respectively, normal values < 2.1 mmol/l). 
Histochemical and biochemical analyses of skeletal muscle were unremarkable, with the 
exception of a mild increased in lipid content in electron microscope images. Motor milestones 
were subsequently delayed: he rolled at 18 months, crawled at 48 months, and walked without 
assistance at nine years of age. His mobility performance was further compromised by the 
development of hip dysplasia at 11 years, for which surgery was required at 16 years, following 
which mobility was reduced to a wheelchair. In the meantime, when he was 10 years old, he was 
diagnosed with adrenal insufficiency and required hydrocortisone replacement.  Since this time, 
the clinical course has been progressive, with gradual worsening of muscle fatigue and weakness 
and dysphagia. When reviewed in our specialist mitochondrial clinic at 18 years of age, he had 
short stature (150 cm) and microcephaly (head circumference of 48.3cm) and was alert and able 
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 to communicate using a light writer. In the limbs, there was generalized dystonia with global 
reduction in strength, symmetrically brisk reflexes, and downgoing plantar responses. Brain MRI 
confirmed partial agenesis of the corpus callosum (Fig. 1B) and a repeat of the metabolic 
investigations was normal, except for a mild elevation of the plasma lactate (2.14 mmol/l normal 
value, 2.1). A second muscle biopsy aged 19 years showed a uniform decrease of cytochrome c 
oxidase (COX) histochemical staining, and complex IV deficiency measured by 
spectrophotometric analysis  (0.007 Complex IV/Citrate Synthase ratio, normal values 0.014-
0.034) and in-gel enzyme activity (Fig. 1C and D). Enzyme assays of complex I and II+III were 
within the normal range. 
 
Exome Sequencing identified a homozygous mutation in MRPS25 in the proband 
With the hypothesis of a mitochondrial aetiology of the disorder, mtDNA was studied in patient 
samples (blood and muscle). The analysis excluded pathogenic point mutations, rearrangements, 
or decreased mtDNA copy number (data not shown); therefore, whole exome sequencing was 
undertaken in both the proband and his parents.  
A series of filtering steps (using Varaft platform (15)) were applied to the identified variants and 
Trio-based analysis performed, considering recessive, de-novo dominant and X-linked 
inheritance pattern (Fig. 2A). A list of rare genetic variants was generated (Supplementary Table 
S1), but none of the variants were consistent with the proband’s phenotype, including the 
agenesis of the corpus callosum. Further filtering against nuclear genes encoding mitochondrial 
proteins yielded two candidate genes: ABCB7 and MRPS25, encoding an ABC transporter and a 
structural subunit of the mitochondrial ribosome, respectively. 
The variant in ABCB7 (c.1472A>G; p.Y491C) on chromosome X has a high frequency in the 
population (MAF=0.001) and is predicted to be benign by multiple in silico tools (SIFT 0.058, 
tolerate, Polyphen2 HDIV 0.028, Benign; Polyphen2 HVAR 0.088, Benign). In contrast, the 
homozygous nucleotide change in MRPS25, c.215C>T; p.P72L, is extremely rare in the general 
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 population (MAF 0.000008 in Genome Aggregation Database, gnomAD, August 2018; absent in 
Exome variant server (ESP6500), and no homozygous cases are listed. Subsequent Sanger 
sequencing of the family members confirmed the variant to be homozygous in the proband’s 
DNA, whereas both parents and the healthy sister were heterozygous carriers for the nucleotide 
change (Fig. 2B). The p.P72 residue is highly conserved (Fig. 2C), and its substitution by leucine 
is predicted to be damaging (SIFT score= 0.03; and PolyPhen-2 score=1 for both HVAR and 
HDVI). The three-dimensional structure of the human ribosome (16)  places mS25 on the solvent 
side of the 28S subunit. Structural modelling suggests that the P72L substitution is likely 
to sterically hinder inter-protein contacts, particularly those with uS17 (Fig. 2D), as well 
as resulting in a secondary destabilisation of the folding of the essential strand-turn-strand in the 
mS25 protein core. The latter potentially compromises the assembly or stability of the 28S 
mitochondrial ribosomal subunit. Thus, both in silico analysis and modelling predict a deleterious 
effect of the p.P72L substitution. 
 
MRPS25-P72L is associated with low levels of the specific polypeptide and its 28S subunit 
partners  
To investigate the effect of the mutation on the MRPS25 protein levels we performed 
immunoblot analysis on fibroblast extracts from the subject and two controls. The steady-state 
level of MRPS25 in the proband’s fibroblasts was approximately one-tenth of the level of the 
controls (Fig. 3A), indicating the mutation causes MRPS25 instability. Since MRPS25 is a 
structural subunit of the 55S ribosome, we investigated whether other MRPS components were 
affected by the lack of MRPS25. The abundance of three other polypeptides of the 28S subunit, 
MRPS17, 22 and 29 was severely affected in the subject’s fibroblasts, while the two components 
of the large mitochondrial ribosomal subunit (MRPL44 and 45) analysed were not decreased (Fig. 
3A). The same contrast between large and small ribosomal subunits was evident in the levels of 
ribosomal RNAs: the 12S rRNA component of the 28S subunit was 60% of the control value, 
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 while the 16S rRNA of the 39S subunit was 1.5 times the control value (Fig. 3B). Moreover, 
analysis of the mitochondrial ribosome profile on sucrose gradients showed that, in the patient 
fibroblasts, there was very little intact 28S subunit, and the residual MRPS components were 
concentrated at the top of the gradient among soluble and individual polypeptides; whereas the 
39S subunit was overall normal, albeit a small fraction distributed at a lower buoyant density than 
controls (Fig. 3C, see also the outcome of complementation, Fig. 6). Together, these data indicate 
that the identified mutation principally affects the assembly or stability of the small ribosomal 
subunits.  
 
Mutant fibroblasts show impaired mitochondrial protein synthesis and multiple respiratory 
chain defects 
The scarcity of the mitoribosomes implies a reduced mitochondrial translation capacity that is 
expected to limit the production of the mtDNA-encoded proteins required for the OXPHOS 
system. Radiochemical labelling of newly synthesized mitochondrial proteins demonstrated that 
mitochondrial translation was compromised in cells with MRPS25-P72L (Fig. 4A). The impaired 
translation was accompanied by decreases in the steady-state levels of proteins of respiratory 
chain complexes I, III and IV (Fig. 4B), with complex III being the least affected of the proton-
translocating enzymes of the respiratory chain (Fig. 4A and B). In contrast, ATP synthase subunit 
6 was translated in amounts similar to control cells, suggesting it takes priority. These findings 
indicate that MRPS25 is required for mitochondrial protein synthesis and that the impairment in 
translation in the mutant fibroblasts results in decreased levels of the mitochondrial respiratory 
chain subunits.  
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 Delivery of wild-type MRPS25 rescues the mitochondrial ribosomal assembly and OXPHOS 
protein levels  
To further validate the pathogenicity of the MRPS25 c.215C>T; p.P72L variant, we performed 
complementation studies by introducing wild-type MRPS25 into immortalized fibroblasts. 
Lentiviral-mediated expression of MRPS25 in control cells resulted in marked cell death, 
suggesting a possible toxic effect of the protein in a context of normal assembly of the 28S 
subunit. In contrast to the controls, transgenic MRPS25 was well tolerated in the cells with the 
MRPS25-P72L variant; where it resulted in the restoration of MRPS levels (Fig. 5A) and the 28S 
subunit (Fig. 6), accompanied by partial restoration of OXPHOS protein levels (Fig. 5B). 
Collectively, these data establish the disease-causing nature of the MRPS25 mutation. 
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 Discussion 
Defects in mitochondrial translation are among the earliest known causes of mitochondrial 
disease, as many result from mutations in the transfer RNA genes that are encoded in mtDNA 
(17). However, over the course of three decades pathological mutations in many components of 
the mitochondrial protein synthesis machinery have been identified, all of which are encoded in 
nuclear DNA (18). Notwithstanding this, deleterious mutations among the 80 structural proteins 
of the mitoribosome are still rare, numbering around 10 MRP genes; moreover, each of these 
accounts for no more than a handful of patients worldwide. The current study adds MRPS25 to 
the set of MRPs whose loss of function causes human disease. Several lines of evidence support 
the pathogenicity of the p.P72L variant: first, the mutation results in a marked reduction of the 
MRPS25 protein (Figure 3A); second, the lack of MRPS25 appears to destabilize the entire small 
ribosomal subunit, which consequently limits the rate of translation (Figs. 3B and 4A), and 
OXPHOS protein levels (Fig. 4B); finally, complementation of the proband’s fibroblasts with 
wild-type MRPS25 restored the 28S subunit and increased the levels of OXPHOS proteins (Figs 5 
and 6).  
 MRPS25 is one of 15 structural subunits of the mitochondrial 28S that does not have a 
bacterial homolog (19). It is therefore the result of the process by which the mitochondrial 
ribosomes have diverged from their bacterial origin by reducing their RNA content and 
increasing the number of proteins. The functional role of MRPS25 has not previously 
investigated; our current analysis indicates that MRPS25 is essential to the assembly or stability 
of the 28S subunit.  
 While it was intuitive that a damaging mutation in MRPS25 would alter the 28S subunit, 
less expected was the effect on the 39S subunit. In addition to the increase in the 16S rRNA (Fig. 
3B), there was a modest shift in the distribution of the 39S subunits (Fig. 3C). That this 
represented a genuine effect of the mutant was corroborated by the analysis of the mutant 
fibroblasts complemented with wild-type MRPS25, where the distribution of the 39S subunits on 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz093/5482278 by Institute of C
hild H
ealth/U
niversity C
ollege London user on 14 M
ay 2019
 the sucrose gradient matched the profile of control cells (Fig. 6A). Revisiting the literature we 
found that other studies have observed alterations to the 39S subunit stemming from defects in 
28S subunit components, although these were not always discussed. In transgenic mice mutated 
for MRPS34 the abundance of large subunits was increased in young animals, and declined in 
aged tissues, associated with alterations of the buoyant density of a fraction of the 39S subunit 
(20). Likewise, complexomic profiling revealed increased abundance of the 39S subunit and 
small changes in its mobility (complex size) in fibroblasts carrying mutant MRPS2 (3). In 
addition, as in our study, a redistribution of the large subunit on sucrose gradients was observed 
in fibroblasts with mutant MRPS34 (9). These alterations to the 39S subunit may reflect abortive 
attempts to form the 55S ribosome, or be the result of unstable 55S subunits breaking apart owing 
to the distortions created by the mutant MRPS25. 
 As with many other mitochondrial diseases, defects in mitochondrial translation cause an 
extremely broad spectrum of symptoms and signs. Nevertheless, there are some consistent 
features among the known mutations in the mitoribosome proteins. The pathological mutation in 
MRPS25 reported here adds to those in MRPS16 and MRPS22 that are also associated with 
defects of the corpus callosum, which, in the case of MRPS25 mutant, was partial. Thus, defects 
in the small subunit of the mitochondrial ribosome should be considered when defects of the 
corpus callosum are present. All three polypeptides are closely juxtaposed in the 28S subunit (Fig. 
7), although mutations in MRPS34, immediately adjacent to MRPS16, result in Leigh or Leigh-
like syndrome (9).  
Overall, brain involvement (structural or functional) is common among disorders that 
arise from mutations in MRPs; in addition to defects of the corpus callosum and Leigh syndrome, 
dilatation of cerebral ventricles and microcephaly have been reported (7). Cardiomyopathy may 
also result from mutations in MRPS genes (7), although it was not evident in our case.  
In conclusion, MRP mutants are a rare but rapidly emerging group of mitochondrial 
translation disorders, which exhibit considerable clinical heterogeneity. Although a whole exome 
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 or genome sequencing approach is frequently required to confirm the diagnosis, early-onset 
multi-system disease associated with structural brain disease on MRI should prompt interrogation 
of this subset of genes. Moreover, our study indicates that defects in the translation machinery 
can result in isolated complex IV deficiency in muscle, rather than in dysfunction of multiple 
respiratory chain enzymes. This observation suggests that dedicated mitochondrial ribosomal 
proteins regulate the translation of specific respiratory chain subunits in mammals, as recently 
proposed for yeasts (25); providing an explanation of the different mitochondrial ribosomal 
profiles among tissues (26), and the tissue specific manifestations of MRP-related diseases.  
 
 
Materials and Methods 
Samples from the proband and family members were obtained after receiving written informed 
consent. The study was performed in accordance with the Declaration of Helsinki and approved 
by our institutional review board.  
 
Histochemical and biochemical studies in skeletal muscle 
Analyses of muscle morphology, histochemistry and respiratory chain activities were performed 
as previously described (21, 22). 
 
Genetic analysis 
DNA was extracted from muscle and peripheral leucocytes by standard methods. For mtDNA 
sequencing, 45 overlapping fragments were amplified and Sanger sequenced using BigDye 
Terminator v1.1. Bi-directional sequencing was run on an ABI 3730xl. Data were assembled and 
analysed by SeqScape v3 using the revised Cambridge Reference sequence (rCRS) NC_012920.1 
for alignment.  
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 The assessment of large-scale rearrangements of mtDNA, both single and multiple deletions in 
muscle was performed by long range PCR.  
Whole exome sequencing was performed on the proband and parents. The samples were prepared 
according to an Agilent SureSelect Target Enrichment Kit preparation guide. The libraries were 
sequenced with HiSeq 2000/2500 sequencer (Illumina). Sequencing data were aligned to the 
human reference genome, hg19 (GRCh37; UCSC genome browser) using Burrows-Wheeler 
Alignment Tool and variants were called using GATK. Filtering of variants was performed using 
VarAft platform (http://varaft.eu/). We filtered out variants with allele frequency higher than 1% 
in gnomAD, 1000 Genome or ESP6500 database, synonymous and deep intronic variants. Finally 
we prioritized variants reported in genes listed in mitocarta (23) and variants associated with the 
phenotype under study. 
Cell culture  
Primary skin fibroblast cultures were obtained from healthy controls and the patient, and 
confirmed free of mycoplasma based on the LookOut Mycoplasma PCR Detection Kit (Sigma). 
Primary fibroblasts were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
LifeTechnologies) supplemented with 10% fetal bovine serum (FBS, Hyclone), 1% penicillin and 
streptomycin (PS, Life Technologies) at 37°C in a 5% CO2 atmosphere. 
 
Western blotting and immunodetection 
For Western blotting cells were lysed in PBS containing 1% SDS, 0.1% n-dodecyl-D-maltoside 
(DDM), 1X protease inhibitor cocktail (Roche), and phosphatase inhibitor cocktail (Abcam) and 
50 Units Benzonase (Millipore). Protein concentration was determined by DC protein assay kit 
(Biorad). Protein samples were prepared in 1× Laemmli loading buffer, heated at 42°C for 15 min 
and resolved on SDS-PAGE gels (Novex, Thermofisher Scientific). After electrophoresis, 
proteins were transferred to polyvinylidene fluoride membranes (PVDF, Millipore). Membranes 
were blocked with 5% non-fat dry milk in PBS with 0.1% (v/v) Tween-20 (PBST) and incubated 
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 overnight at 4°C with the primary antibodies listed in Supplementary Table S2. Membranes were 
then washed three times with PBST and incubated with HRP-conjugated secondary antibodies 
(Promega) at 1:5000 dilution in 5% milk PBST. After three washes, immunoblots were developed 
using enhanced chemiluminescence (ECL Prime, GE Healthcare). 
 
[35S]-methionine cell labelling for mitochondrial protein synthesis 
Mitochondrial translation products were labelled using 35S-methionine as previously described 
(24). Fibroblasts were washed twice with methionine/cysteine free DMEM (Life Technologies) 
supplemented with 1 mM L-glutamax, 96 μg/ml cysteine (Sigma), 1mM pyruvate and 5 % (v/v) 
dialyzed FBS, and incubated in the same medium for 10 min at 37°C. 100 μg/ml emetine 
dihydrochloride (Sigma) was then added to inhibit cytosolic translation, before pulse-labelling 
with 100 μCi [35S]-methionine for 45-60 minutes. Cells were chased for 10 min at 37°C in regular 
DMEM with 10% FBS, washed three times with PBS and collected. Labelled cells were lysed in 
PBS, 0.1% n-dodecyl-D-maltoside (DDM), 1% SDS, 50 units Benzonase (Millipore), 1X 
protease inhibitor cocktail (Roche). Protein concentration was measured by DC protein assay kit 
(Biorad) and 20 µg of protein were separated by 12% SDS-PAGE. Gel were fixed and vacuum 
dried, and exposed to X-ray film for 1 week. 
 
RNA quantification  
Total RNA was isolated from controls and patient fibroblasts using Pure Link™ RNA Mini Kit 
(Ambion). Quantitative RT-PCR was performed in triplicate on 384-Well reaction plates using a 
7900HT Fast Real-Time PCR System (Applied Biosystems). 50 ng total RNA was retro-
transcribed and amplified in “one-step” reactions using QuantiFast SYBR Green RT-PCR Kit 
(QIAGEN). Expression of 12S and 16S rRNA was normalized to expression of the housekeeping 
ß-actin gene (ACTB) and results were represented as fold changes in the patient relative to 
controls. Primer-sequences are listed in Supplementary Table S3. 
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 Sucrose gradient sedimentation 
5 x106 fibroblasts were lysed in 700 ul of lysis buffer (40 mM Tris-HCl, pH 7.6, 150 mM NaCl, 
20 mM MgCl2, 1% n-dodecyl-D-maltoside (DDM), 1mM PMSF, 1X protease inhibitors without 
EDTA, 0.08 U/mL RNasin) on ice for 45 minutes. Lysates were cleared by centrifugation at 
12000x g for 40 minutes and 1 mg lots of protein were loaded onto a 10%-30% linear sucrose 
gradient. Gradients were prepared in 40 mM Tris-HCl, 150 mM NaCl, 20 mM MgCl2, 1mM 
PMSF, 1X protease inhibitors without EDTA, using a gradient master (Biocomp), according to 
the manufacturer instructions. Samples were centrifuged at 71000x g for 16 hours in a Beckman 
SW41 rotor at 4°C. After centrifugation, 16 fractions of 750 µl each were collected from the top 
of the gradient and analysed by immunoblotting. For MRPS25 analysis, the protein content of 
each fraction was concentrated by TCA precipitation before western blot analysis. 
 
Lentiviral expression of wild-type MRPS25  
MRPS25cDNA clone (BC003590.2) was obtained from BioCat GmbH (Heidelberg, Germany). A 
MRPS25-Flag construct was generated with a pair of oligonucleotides (forward primer: 5´- Ctt 
ctt Gaa Ttc acc atg cccatgaagggccgcttccccatc -3´, reverse primer: 5´-
 ctctct aagctt cta cttatcgtcgtcatccttgtaatc gtcctgggcatcggctttca-3 )´, that include EcoRI and HindIII 
restriction sites and the Flag tag, and was inserted into pENTR vector (Life Technologies, 
Darmstadt, Germany). After generating an entry clone, the pLenti CMV Blast DEST MRPS25-
Flag expressing vector (Addgene plasmid #17451) was created using LR recombination. The 
pLenti CMV Blast DEST MRPS25-Flag expressing vector and packaging plasmids pMD2.G and 
psPAX2 (Addgene plasmid #12259 and #12260) were transfected into HEK-293FT cells with 
lipofectamin 2000 (Life Technologies, ThermoFisher Scientific, Darmstadt, Germany) and OPTI-
MEM media (Life Technologies, ThermoFisher Scientific, Darmstadt, Germany) to produce the 
lentivirus. The recombinant lentiviral constructs were transduced into the fibroblast cell lines that 
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 had been immortalized by retroviral expression of the HPV-16 E6E7 gene. Stable cell lines 
expressing the MRPS25-Flag protein were generated by blasticidin (Invitrogen) selection. 
 
Modelling of human MRPS25 
Multiple sequence alignment was done using the Clustal Omega 
(https://www.ebi.ac.uk/Tools/msa). The structural model image was prepared with the PyMOL 
Molecular Graphics System, Version 1.2r3pre, Schrödinger, LLC. 
 
 
Statistics 
Statistical analyses were performed using Graphpad Prism v.7.04. Immunoblots and 
mitochondrial protein synthesis were analyzed with Fiji ImageJ. T-test was used for comparing 
two independent groups. P-values <0.05 were considered to be statistically significant.  
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 Figure Legends 
 
Figure 1. Neuroradiological and histological findings. A) Pedigree of the family; the proband 
is indicated by the black arrow. B) T1 Sagittal Brain MRI showing partial agenesis of corpus 
callosum (yellow arrowheads). C) Cytochrome c oxidase staining (i) reveals a mild and 
generalized decreased activity with rare fibres with subsarcolemmal mitochondrial aggregates 
typical of ‘ragged-red’ alterations (succinate dehydrogenase, ii). D) Complex IV in-gel activity is 
decreased in the proband’s muscle sample. 
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Figure 2. Identification of a potential pathological MRPS25 mutation by exome sequencing. 
A) Filtering of the identified variants was performed using Varaft platform by comparing 
proband’s with parents’ exomes. The analysis resulted in 42 single nucleotide variants (de novo, 
recessive and X- linked), of which two were in genes encoding for mitochondrial proteins. Only 
the c.215C>T change in MRPS25 was predicting damaging (using SIFT and Polyphen tools). B) 
Sanger sequencing confirmed that each parent and the healthy sister were heterozygous (asterix) 
for the mutation in MRPS25 while the affected patient was homozugous (arrow). C) Sequencing 
alignment of the human MRPS25 protein shows the evolutionary conservation of the Pro72. D) 
The modelling of Pro72Leu (stick representation) mutation on the structure of the human 
mitoribosome (PDBID: 3J9M) reveals that it is likely to sterically hinder the formation of 
interprotein contacts with uS17 (yellow) as well as result in a potential destabilisation of 
the folding of the essential strand-turn-strand in the mS25 (cyan) protein core. The inset of the 
mitoribosomal structure illustrates the relative position of uS17-mS25 (surface representation) on 
the small subunit (yellow cartoon). 
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Figure 3. MRPS25 mutation compromises the maintenance of normal 28S subunit levels. A) 
Steady state levels of small (MRPS25, MRPS17, MRPS29 and MRPS22) and large (MRPL45, 
MRPL44) mitoribosomal subunits in controls (C1 and C2) and patient (P) total fibroblast extracts. 
Vinculin (VCL) is shown as a loading control. The mean relative abundances are shown to the 
right based on Fiji ImageJ densitometric analysis. Data are expressed as mean ± standard error of 
the mean of n=3 independent experiments, except MRPL27 and MRPS29 (n=2). Probability was 
determined using Welch’s t-test (ns=not significant, (p>0.05); *p<0.05; ***p<0.001). B) Relative 
12S and 16S rRNA levels in patient-derived fibroblasts. The data are representative of 2 
independent experiments. C) Isokinetic sucrose gradients (10-30%) were used to analyze the 
distribution of mitochondrial ribosome in total lysates from control (C) and patient (P) fibroblasts. 
Mitochondrial ribosomal protein markers of the mt-SSU (MRPS27 and MRPS22) and the mt-
LSU (MRPL13 and MRPL44) ribosomal subunits were detected by immunoblotting. The data are 
representative of three independent experiments. 
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Figure 4. MRPS25 mutation reduced mitochondrial translation and causes a combined 
OXPHOS defects in the affected patient. A) De novo mitochondrial protein synthesis measured 
by 35S-methionine incorporation in control (C1) and patient (P) fibroblasts. The gel image is 
flanked by polypeptide assignments to the left and plot profiles showing the pixel intensities for 
the control (black line) and patient (PT – red line) are shown on the right. Coomassie staining of 
total protein was used as loading control. B) To the left, representative immunoblots of OXPHOS 
components of complex I (NDUFA9), complex III (UQCRC1), complex IV (COXII) and 
complex V (ATP5A). Levels of Vinculin (VCL) were used as indicators of protein loading. To 
the right, a chart indicating the abundance of the respiratory chain proteins in the patient 
fibroblasts compared to controls (Fiji ImageJ densitometric analysis). The data are the mean ± 
standard error of the mean of n≥3 independent experiments. Probability was determined using 
Welch’s t-test (ns=not significant, p>0.05; ***p<0.001). 
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Figure 5. Lentivirus mediated expression of wild-type MRPS25 rescues the mt-SSU and 
OXPHOS levels in patient cells. Analysis of the small (MRPS25, MRPS17, MRPS27, 
MRPS22) and large (MRPL45) mitochondrial subunits (A) and OXPHOS components of 
complex I (NDUFB8), complex III (UQCRC2), complex IV (COXI) (B) in immortalized cell 
extracts from control (C1 and C2), patient (P) and patient transduced with wild-type MRPS25 
(PS25). Vinculin (VCL) was used as a loading control. To the right of A and B, relative abundance 
of the ribosomal protein and OXPHOS components in untransduced versus the transduced 
fibroblasts (Fiji ImageJ densitometric analysis). The data are shown as the mean ± standard error 
of the means of n≥3 independent experiments. Probability was determined using Welch’s t-test 
(ns=not significant, (p>0.05); *p<0.05). 
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Figure 6. Rescue of the mitoribosomes assembly in patient cells transduced with wild-type 
MRPS25. A) Mitochondrial ribosomes from controls (C1 and C2) and patient without (P) and 
with (PS25) wild-type MRPS25 cDNA were sedimented on sucrose gradient and fractions 
separated by SDS-PAGE. Mitochondrial ribosomal protein markers of the mt-SSU (MRPS27) 
and the mt-LSU (MRPL13 and MRPL44) were detected by immunoblotting. The data are 
representative of two independent experiments. B) As in A, except that MRPS25 protein 
distribution was analysed.  
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 Figure 7. The 28S subunit and mitochondrial disease. Schematic representation of the 
mitochondrial 28S subunit with circles representing each of the 30 constituent proteins. Numbers 
in the circles are specific MRPS associated with mitochondrial disease. Defect in MRPS16, 
MRPS22 and MRPS25, closely juxtaposed in the 28S subunit, are associated with agenesis of 
corpus callosum. 
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